William Berrigan

Dr. William Berrigan

Emory School of Medicine
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 March 2024 in Arthroscopy
Verified
Journal Article
Open access
WBWilliam Berrigan
William Berrigan
ZBZach Bailowitz
Zach Bailowitz
APAnna Park
Anna Park
ARAakash Reddy
Aakash Reddy
RLRyan Liu
Ryan Liu
DLDrew Lansdown
Drew Lansdown
Purpose: To determine whether the platelet dose administered during a platelet‐rich plasma (PRP) injection for knee osteoarthritis (OA) affects clinical outcomes. Methods: A systematic review was performed by searching PubMed, Cochrane Library, and Embase for randomized controlled trials with at least 1 study arm using PRP for knee OA. Only studies that provided a platelet count, concentration, or dose with a minimum of 6‐month outcome scores were included. Studies in which the PRP group had statistically significant positive outcomes were separated from those without statistical significance. The average platelet doses for studies with positive outcomes in the PRP group were compared with those without positive outcomes. Results: After exclusion criteria were applied, 29 studies were analyzed. Of the 29, there were 31 arms that used PRP as a treatment method, of which 28 had statistically significant positive outcomes at 6 months compared with the control group. The mean platelet dose in the 28 with a positive outcome was 5,500 ± 474 × 10 6 , whereas the 3 that had no positive difference had a mean platelet dose of 2,302 ± 437 × 10 6 ( P < .01). There were 18 studies with 12‐month outcomes, with 16 of 18 having positive outcomes. The positive studies had an average platelet dose of 5,464 ± 511, whereas the studies that had no statistical difference had an average platelet dose of 2,253 ± 753 × 10 6 ( P < .05). Conclusions: Improved clinical outcomes from PRP injections for knee OA may be related to a greater platelet dose. Level of Evidence: Level II, systematic review of Level I and II studies.

27 September 2024 in Current Reviews in Musculoskeletal Medicine
Verified
Journal Article
Open access
PDF file
WBWilliam Berrigan
William Berrigan
FTFrances Tao
Frances Tao
JKJoel Kopcow
Joel Kopcow
APAnna L. Park
Anna L. Park
IAIsabel Allen
Isabel Allen
ZBZachary Bailowitz
Zachary Bailowitz
Purpose of Review: This study aims to systematically review platelet dosage in platelet rich plasma (PRP) injections for common musculoskeletal conditions. Recent Findings: Notable heterogeneity exists in the literature regarding platelet dosage. Clinical studies indicate that a higher dosage may lead to improved outcomes concerning pain relief, functional improvement, and chondroprotection in knee osteoarthritis (OA). However, the impact of dosing on other musculoskeletal pathologies remains uncertain. Our investigation identifies a potential dose-response relationship between platelet dose and PRP effectiveness for knee OA treatment, pinpointing an optimal threshold of greater than 10 billion platelets for favorable clinical outcomes. Notably, this effect appears more pronounced for functional outcomes than for pain relief. For other conditions, a lower dosage may suffice, although the existing literature lacks clarity on this matter. Summary: PRP dosage may significantly influence treatmentoutcomes, particularly in knee OA. Further research is warranted to elucidate optimal dosages for varying conditions.

31 August 2023 in Current Reviews in Musculoskeletal Medicine
Verified
Journal Article
Open access
PDF file
RPRosa M. Pasculli
Rosa M. Pasculli
ECElizabeth A. Callahan
Elizabeth A. Callahan
JWJames Wu
James Wu
NENiam Edralin
Niam Edralin
WBWilliam Berrigan
William Berrigan
: Purpose: To serve as a guide for non-operative physicians in the management of femoroacetabular impingement syndrome and provide an algorithm as to when to refer patients for potential surgical management. Recent Findings: Supervised physical therapy programs that focus on active strengthening and core strengthening are more effective than unsupervised, passive, and non-core-focused programs. There is promising evidence for the use of intra-articular hyaluronic acid and PRP as adjunct treatment options. Recent systematic reviews and meta-analyses have found that in young active patients, hip arthroscopy demonstrates improved short-term outcomes over physical therapy. Summary: The decision for the management of FAIS is complex and should be specific to each patient. Consideration of the patient’s age, timing to return to sport, longevity of treatment, hip morphology, and degree of cartilage degeneration is required to make an informed decision in the treatment of these patients.

30 September 2020 in Toxins
Verified
Journal Article
Open access
PDF file
MFMichael Farrell
Michael Farrell
Barbara KarpBarbara Karp
Barbara Karp
PKPanagiotis Kassavetis
Panagiotis Kassavetis
WBWilliam Berrigan
William Berrigan
SYSimge Yonter
Simge Yonter
KAKatharine Alter
Katharine Alter
Chemodenervation of cervical musculature using botulinum neurotoxin (BoNT) is established as the gold standard or treatment of choice for management of Cervical Dystonia (CD). The success of BoNT procedures is measured by improved symptomology while minimizing side effects and is dependent upon many factors including: clinical pattern recognition, identifying contributory muscles, BoNT dosage, and locating and safely injecting target muscles. In patients with CD, treatment of anterocollis (forward flexion of the neck) and anterocaput (anterocapitis) (forward flexion of the head) are inarguably challenging. The longus Colli (LoCol) and longus capitis (LoCap) muscles, two deep cervical spine and head flexor muscles, frequently contribute to these patterns. Localizing and safely injecting these muscles is particularly challenging owing to their deep location and the complex regional anatomy which includes critical neurovascular and other structures. Ultrasound (US) guidance provides direct visualization of the LoCol, LoCap, other cervical muscles and adjacent structures reducing the risks and side effects while improving the clinical outcome of BoNT for these conditions. The addition of electromyography (EMG) provides confirmation of muscle activity within the target muscle. Within this manuscript, we present a technical description of a novel US guided approach (combined with EMG) for BoNT injection into the LoCol and LoCap muscles for the management of anterocollis and anterocaput in patients with CD.

21 October 2022 in Bone Reports
Verified
Journal Article
Open access
RPRosa M. Pasculli
Rosa M. Pasculli
CKCharles D. Kenyon
Charles D. Kenyon
WBWilliam Berrigan
William Berrigan
KMKenneth Mautner
Kenneth Mautner
KHKyle Hammond
Kyle Hammond
PJPrathap Jayaram
Prathap Jayaram
Subchondral bone marrow lesions (BMLs) are areas of disease within subchondral bone that appear as T1 hypointense and T2 hyperintense ill-defined areas of bone marrow on magnetic resonance imaging. The most common bone marrow lesions include subchondral lesions related to osteoarthritis, osteochondral defects, and avascular necrosis. Emerging therapies include autologous biologic therapeutics, in particular mesenchymal stem cells (MSCs), to maintain and improve cartilage health; MSCs have become a potential treatment option for BMLs given the unmet need for disease modification. Active areas in the preclinical research of bone marrow lesions include the paracrine function of MSCs in pathways of angiogenesis and inflammation, and the use of bioactive scaffolds to optimize the environment for implanted MSCs by facilitating chondrogenesis and higher bone volumes. A review of the clinical data demonstrates improvements in pain and functional outcomes when patients with knee osteoarthritis were treated with MSCs, suggesting that BM-MSCs can be a safe and effective treatment for patients with painful knee osteoarthritis with or without bone marrow lesions. Preliminary data examining MSCs in osteochondral defects suggest they can be beneficial as a subchondral injection alone, or as a surgical augmentation. In patients with hip avascular necrosis, those with earlier stage disease have improved outcomes when core decompression is augmented with MSCs, whereas patients in later stages post-collapse have equivalent outcomes with or without MSC treatment. While the evidence for the use of MSCs in conditions with associated bone marrow lesions seems promising, there remains a need for continued investigation into this treatment as a viable treatment option.

1 April 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
WBWilliam Berrigan
William Berrigan
KCKevin Cipriano
Kevin Cipriano
KEKirk A Easley
Kirk A Easley
KMKen Mautner
Ken Mautner
(1) Background: Patellar and Achilles tendon injuries have become increasingly prevalent, particularly among active populations and athletes, leading to significant functional impairments. While B-Mode ultrasound has been useful in the diagnosis of these injuries, its capacity to assess tendon mechanical properties, such as stiffness, is limited. Shear wave elastography (SWE) offers a promising alternative by measuring tissue stiffness, which may enhance the evaluation of tendon health. Previous studies have established that SWE can differentiate healthy tendons from those with pathological changes. However, reference values for specific tendon types, including the patellar and Achilles tendons, remain limited. This study aims to provide preliminary baseline SWE values for these tendons in a healthy cohort. (2) Methods: In this cross-sectional study, healthy volunteers aged 18–65, with no history of lower extremity injury, were assessed using a Samsung RS85 Prestige ultrasound system with a 14L-2 MHz transducer. SWE measurements were obtained from the patellar tendon at a single location and from the Achilles tendon at both the midportion and insertional sites. All assessments followed a standardized protocol to ensure consistency and minimize variability. (3) Results: A total of 54 healthy adult participants were included. The mean SWE value for the patellar tendon was 96.3 (SD = 10.9 kPa), with males showing significantly higher stiffness than females (99.3 kPa vs. 93.8 kPa, p = 0.009). A higher BMI was associated with lower stiffness in the patellar tendon. The mean SWE values for the Achilles tendon were 101.7 (SD = 16.2 kPa) at the insertion and 145.6 (SD = 18.8 kPa) at the midportion. (4) Conclusions: This study provides SWE values for the patellar and Achilles tendons in healthy individuals, which can serve as a foundation for future research and clinical applications. These values may help in the comparison of healthy and pathological tendons, particularly in the context of tendinopathies, tendon tears, and treatment monitoring. While shear wave elasticity shows promise as a tool for diagnosing and monitoring tendon injuries and degeneration, more research is required to establish its precise reliability and validity in clinical practice.